Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in the upcoming Jefferies Global Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in the upcoming Jefferies Global Health Care Conference. The presentation is scheduled for Wednesday, June 4th, 2025, at 12:50 PM ET in New York. Investors and interested parties can access the presentation webcast and replay through Oruka's investor events website at ir.orukatx.com.
Details
News Market Reaction – ORKA
The recorded move for ORKA in the trading session of this news was -0.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY:
Date: Wednesday, June 4th, 2025
Time: 12:50PM ET
A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.